Probiotic use may decrease risk factors for metabolic syndrome
1. Patients randomized to receive 12 weeks of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics were observed to have ...
Tag: Gastroenterology
Grading carcinoembryonic antigen levels can enhance prognostic stratification in colorectal cancer
1. Higher CEA levels in patients with colorectal cancer are indicative of aggressive tumour phenotypes and survival Evidence Rating Level: ...
Astellas: Vyloy improves survival in patients with advanced gastric cancer
Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher ...
Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares
1. The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
Glucagon-like peptide-1 receptor agonists may impact outcomes of endoscopy
1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
2 Minute Medicine Rewind October 28, 2024
Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration 1. The use of memantine and donepezil for ...
High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver
1. Increased levels of hypersensitive C-reactive protein was associated with increased risk of non-alcoholic fatty liver disease among non-obese individuals. ...
2 Minute Medicine Rewind October 21, 2024
In Utero Exposure to Maternal COVID-19 and Offspring Neurodevelopment Through Age 24 Months 1. In utero exposure to maternal COVID-19 ...
Liver transplantation plus chemotherapy improves survival in patients with unresectable colorectal liver metastases
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group compared to chemotherapy alone. 2. Serious adverse ...
Tulisokibart effectively induces clinical remission in moderately to severely active ulcerative colitis
1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed ...
